Patient characteristics (N = 50)
Characteristics . | Values . |
---|---|
Age ≥75 y, n (%) | 26 (52) |
Median age (range), y | 75 (66-84) |
Male, n (%) | 29 (58) |
ECOG status, n (%) | |
0 to 1 | 43 (86) |
2 | 7 (14) |
AML type, n (%) | |
De novo | 33 (66) |
Secondary | 12 (24) |
MDS | 10 (20) |
MPN | 2 (4) |
Therapy-related | 5 (10) |
AML FAB classification, n (%) | |
M0 | 5 (10) |
M1 | 7 (14) |
M2 | 19 (38) |
M4 | 8 (16) |
M5 | 3 (6) |
M6 | 2 (4) |
Unknown | 6 (12) |
Cytogenetic risk group, n (%) | |
Intermediate | 27 (54) |
Cytogenetically normal | 21 (42) |
Cytogenetically abnormal | 6 (12) |
High | 21 (42) |
Median peripheral blood blasts (range), % | 2 (0-77) |
Median BM blasts (range), % | 40 (20-89) |
Median hemoglobin (range), g/dL | 9.3 (6.5-15.3) |
Median platelets (range), ×109/L | 45.5 (9-639) |
Median white blood cell count (range), ×109/L | 2.6 (0.8-29.6) |
Median ANC (range), ×109/L | 0.58 (0-6.8) |
Median creatinine (range), mg/dL | 0.9 (0.5-1.6) |
Median bilirubin (range), mg/dL | 0.6 (0.2-5) |
Characteristics . | Values . |
---|---|
Age ≥75 y, n (%) | 26 (52) |
Median age (range), y | 75 (66-84) |
Male, n (%) | 29 (58) |
ECOG status, n (%) | |
0 to 1 | 43 (86) |
2 | 7 (14) |
AML type, n (%) | |
De novo | 33 (66) |
Secondary | 12 (24) |
MDS | 10 (20) |
MPN | 2 (4) |
Therapy-related | 5 (10) |
AML FAB classification, n (%) | |
M0 | 5 (10) |
M1 | 7 (14) |
M2 | 19 (38) |
M4 | 8 (16) |
M5 | 3 (6) |
M6 | 2 (4) |
Unknown | 6 (12) |
Cytogenetic risk group, n (%) | |
Intermediate | 27 (54) |
Cytogenetically normal | 21 (42) |
Cytogenetically abnormal | 6 (12) |
High | 21 (42) |
Median peripheral blood blasts (range), % | 2 (0-77) |
Median BM blasts (range), % | 40 (20-89) |
Median hemoglobin (range), g/dL | 9.3 (6.5-15.3) |
Median platelets (range), ×109/L | 45.5 (9-639) |
Median white blood cell count (range), ×109/L | 2.6 (0.8-29.6) |
Median ANC (range), ×109/L | 0.58 (0-6.8) |
Median creatinine (range), mg/dL | 0.9 (0.5-1.6) |
Median bilirubin (range), mg/dL | 0.6 (0.2-5) |
ANC, absolute neutrophil count; FAB, French-American-British; MPN, myeloproliferative neoplasm.